111 related articles for article (PubMed ID: 7340443)
1. Non-platelet-mediated vascular actions of 1-O-alkyl-2-acetyl-sn-3-glyceryl phosphorycholine (a synthetic PAF).
Sánchez Crespo M; Alonso F; Iñarrea P; Egido J
Agents Actions; 1981 Dec; 11(6-7):565-6. PubMed ID: 7340443
[TBL] [Abstract][Full Text] [Related]
2. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism.
Sánchez-Crespo M; Alonso F; Iñarrea P; Alvarez V; Egido J
Immunopharmacology; 1982 Apr; 4(2):173-85. PubMed ID: 7085259
[TBL] [Abstract][Full Text] [Related]
3. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.
Tanaka S; Kasuya Y; Masuda Y; Shigenobu K
J Pharmacobiodyn; 1983 Nov; 6(11):866-73. PubMed ID: 6668545
[TBL] [Abstract][Full Text] [Related]
4. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
5. The role of Ca2+ in regulating the catabolism of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in rabbit platelets.
Touqui L; Shaw AM; Dumarey C; Jacquemin C; Vargaftig BB
Biochem J; 1987 Jan; 241(2):555-60. PubMed ID: 3109377
[TBL] [Abstract][Full Text] [Related]
6. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the actions of some platelet-activating factor antagonists on platelets and aortic smooth muscles.
Teng CM; Yu SM; Ko FN; Chen CC; Wang WC; Chen KY; Huang YL; Huang TF
Eur J Pharmacol; 1991 Nov; 205(2):151-6. PubMed ID: 1812005
[TBL] [Abstract][Full Text] [Related]
8. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.
Filep JG; Sirois MG; Rousseau A; Fournier A; Sirois P
Br J Pharmacol; 1991 Dec; 104(4):797-804. PubMed ID: 1667286
[TBL] [Abstract][Full Text] [Related]
9. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP
J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357
[TBL] [Abstract][Full Text] [Related]
10. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
11. Effect of lysolecithin on blood vessel reactivity and of some ethers and esters of glycerophosphocholine and phosphocholine, respectively, on aggregation of rat platelets.
Bekemeier H; Bakathir HA; Giessler AJ; Hirschelmann R; Nuhn P
Agents Actions; 1981 Dec; 11(6-7):563-5. PubMed ID: 7340442
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo.
Yue TL; Rabinovici R; Farhat M; Feuerstein G
Prostaglandins; 1990 May; 39(5):469-80. PubMed ID: 2353116
[TBL] [Abstract][Full Text] [Related]
13. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).
Demopoulos CA; Pinckard RN; Hanahan DJ
J Biol Chem; 1979 Oct; 254(19):9355-8. PubMed ID: 489536
[TBL] [Abstract][Full Text] [Related]
14. PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover.
Catalán RE; Martínez AM; Aragonés MD; Lombardía M; Garde E
Eur J Pharmacol; 1995 Aug; 290(3):183-8. PubMed ID: 7589212
[TBL] [Abstract][Full Text] [Related]
15. Platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position.
Wykle RL; Surles JR; Piantadosi C; Salzer WL; O'Flaherty JT
FEBS Lett; 1982 May; 141(1):29-32. PubMed ID: 7084476
[No Abstract] [Full Text] [Related]
16. Structural features of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) required for hypotensive and platelet serotonin responses.
Blank ML; Cress EA; Lee TC; Malone B; Surles JR; Piantadosi C; Hajdu J; Snyder F
Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):3-20. PubMed ID: 7146619
[TBL] [Abstract][Full Text] [Related]
17. Transient activation of the acetyltransferase necessary for paf-acether biosynthesis in thrombin-activated platelets.
Coëffier E; Ninio E; Le Couedic JP; Chignard M
Br J Haematol; 1986 Apr; 62(4):641-51. PubMed ID: 3964558
[TBL] [Abstract][Full Text] [Related]
18. Natural 1-O-alkylglycerols reduce platelet-activating factor-induced release of [3H]-serotonin in rabbit platelets.
Pédrono F; Cheminade C; Legrand AB
Prostaglandins Leukot Essent Fatty Acids; 2004 Jul; 71(1):19-23. PubMed ID: 15172680
[TBL] [Abstract][Full Text] [Related]
19. Effect of PAF on rat lung vascular permeability: role of platelets and polymorphonuclear leucocytes.
Sirois MG; de Lima WT; de Brum Fernandes AJ; Johnson RJ; Plante GE; Sirois P
Br J Pharmacol; 1994 Apr; 111(4):1111-6. PubMed ID: 8032597
[TBL] [Abstract][Full Text] [Related]
20. 1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants.
O'Flaherty JT; Wykle RL; Miller CH; Lewis JC; Waite M; Bass DA; McCall CE; DeChatelet LR
Am J Pathol; 1981 Apr; 103(1):70-8. PubMed ID: 7223864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
